Telesis Bio, Inc. (TBIO)
Sector: Medical - Devices
Industry: Medical - Devices
Telesis Bio, Inc.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 12, 2026 | 0.0100 | 0.0100 | 0.0100 | 0.0100 | 113 |
| Nov 9, 2026 | 0.0100 | 0.0100 | 0.0100 | 0.0100 | 1,325 |
| Nov 6, 2026 | 0.0110 | 0.0110 | 0.0110 | 0.0110 | 813 |
| Nov 5, 2026 | 0.0120 | 0.0120 | 0.0120 | 0.0120 | 455 |
| Oct 30, 2026 | 0.0100 | 0.0100 | 0.0100 | 0.0100 | 100 |
| Oct 15, 2026 | 0.0386 | 0.0386 | 0.0386 | 0.0386 | 135 |
| Oct 14, 2026 | 0.0110 | 0.0400 | 0.0110 | 0.0400 | 405 |
| Oct 13, 2026 | 0.0110 | 0.0110 | 0.0110 | 0.0110 | 2,059 |
| Oct 7, 2026 | 0.0110 | 0.0110 | 0.0110 | 0.0110 | 205 |
Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide.
Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries; and short oligo ligation assembly enzymatic DNA synthesis.
It also serves government institutions, contract research organizations, and synthetic biology companies.
The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
30d Avg
561
60d Avg
631
90d Avg
1.16K
Telesis Bio, Inc. (OTC: TBIO) traded at $0.0100 on Nov 12, 2026, unchanged from the previous close of $0.0100. 52-week range: $0.0010 to $0.1500. The company is in the Healthcare sector (Medical - Devices).